Imen Hammami
A5093408650- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
- Antiplatelet Therapy and Cardiovascular Diseases
- Retinal Imaging and Analysis
- Fatty Acid Research and Health
- Eicosanoids and Hypertension Pharmacology
- Inflammatory mediators and NSAID effects
- Peroxisome Proliferator-Activated Receptors
- Corneal surgery and disorders
- Atrial Fibrillation Management and Outcomes
- Diabetes Treatment and Management
University of Oxford
2023-2025
Background and aims In the primary prevention setting, low-dose aspirin reduces major vascular events (MVEs) by approximately 11% but increases bleeding (MB) 40–50%, implying that net benefit will be most evident when MVE-to-MB ratio is >4. This study aimed to derive cross-validated risk scores for MB MVE use identify groups who may differing benefits from treatment. Methods 431 167 UK Biobank participants without known atherosclerotic cardiovascular disease at baseline were followed...
Purpose Aspirin and omega-3 fatty acids (FAs) are potential disease modifiers of age-related macular degeneration (AMD), but previous studies have produced inconsistent findings. Randomised evidence for the efficacy safety aspirin FAs on AMD is presented in this study. Design ASCEND-Eye a substudy eye effects 2×2 factorial design ASCEND (A Study Cardiovascular Events iN Diabetes) double-blind, randomised, placebo-controlled trial primary prevention cardiovascular events. Reports diagnoses...
<title>Abstract</title> <bold>Background:</bold> The double-blind, 2x2 factorial design, placebo-controlled ASCEND randomized trial compared the effects of 100mg aspirin daily and, separately, 1g omega-3 fatty acids (FAs) on primary prevention cardiovascular disease in 15,480 UK adults with diabetes. We report these treatment allocations scores derived from National Eye Institute’s Visual Function Questionnaire-25 (NEI-VFQ-25) a subset participants involved ASCEND-Eye sub-study....
Abstract Background The double-blind, 2 × factorial design, placebo-controlled ASCEND randomized trial compared the effects of 100 mg aspirin daily and, separately, 1 g omega-3 fatty acids (FAs) on primary prevention cardiovascular disease in 15,480 UK adults with diabetes. We report these treatment allocations scores derived from National Eye Institute’s Visual Function Questionnaire-25 (NEI-VFQ-25) a subset participants involved ASCEND-Eye sub-study. Methods Ordinal data NEI-VFQ-25 were...